Patient Outcomes 10 Years After Ibrutinib Therapy
May 24, 2024
Long-term follow-up data confirms the sustained benefit of ibrutinib therapy for CLL / SLL, including uMRD, in a small subset of patients.
Long-term follow-up data confirms the sustained benefit of ibrutinib therapy for CLL / SLL, including uMRD, in a small subset of patients.
A combination of ibrutinib plus venetoclax is a very effective first-line treatment for CLL, and 90% of patients are progression-free after five years.
The FDA approved an oral suspension of ibrutinib for adults with chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL).
Patients with relapsed/refractory CLL / SLL treated with zanubrutinib had longer remissions than patients treated with ibrutinib.
Measurable residual disease (MRD)-guided treatment of CLL with ibrutinib plus venetoclax significantly increased time in remission.
Mutations at BTK C481 are the most common mutations seen in pooled trial data of chronic lymphocytic leukemia (CLL) patients on ibrutinib, leading to resistance and progressive disease (PD).
A newly published paper in JAMA Oncology found that among cancer patients with suspected ibrutinib-related cardiotoxic effects, the presence of heart muscle injury and scarring is high, and this is associated with an increased risk of developing future cardiovascular adverse events.
For most CLL (chronic lymphocytic leukemia) patients who have received six years of continuous ibrutinib treatment, the levels of residual disease decrease or remain stable for the subsequent 6-12 months after stopping ibrutinib.
With a four-year follow-up, fixed-duration I + V continues to provide deep, durable remissions with clinically meaningful progression-free survival (PFS) and time off treatment, including in patients with high-risk disease features.